secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALATIN TECHNOLOGIES INC (PTN)
CIK:        0000911216
Form:       8-K
Filed at:   2025-08-18T23:59:59+00:00
Accession:  0001654954-25-009743
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palatin signs up to €280M collaboration with Boehringer for retinal disease therapies
--------------------------------------------------------------------------------

- €2M upfront, up to €18M near-term milestones, up to €260M in regulatory/commercial milestones plus tiered royalties.
- Collaboration focuses on melanocortin receptor agonists for diabetic retinopathy and DME; Boehringer funds two-year research.
- Palatin assigned patent rights to Boehringer; potential first-in-class treatment targeting inflammation, vascular dysfunction, neurodegeneration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/911216/000165495425009743/0001654954-25-009743-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/911216/000165495425009743/ptn_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-25-009743

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer